BridgeBio Pharma Gross Profit 2018-2023 | BBIO
BridgeBio Pharma gross profit from 2018 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
BridgeBio Pharma Annual Gross Profit
(Millions of US $) |
| 2023 |
$7 |
| 2022 |
$74 |
| 2021 |
$67 |
| 2020 |
$8 |
| 2019 |
$38 |
| 2018 |
$ |
| 2017 |
$ |
BridgeBio Pharma Quarterly Gross Profit
(Millions of US $) |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$3 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$-0 |
| 2022-06-30 |
$73 |
| 2022-03-31 |
$0 |
| 2021-12-31 |
$11 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$54 |
| 2021-03-31 |
$0 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$8 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
$14 |
| 2019-09-30 |
$24 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.375B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
